X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Down 14.3% in February

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 9,480,000 shares, a decrease of 14.3% from the February 13th total of 11,060,000 shares. Based on an average daily volume of 4,100,000 shares, the days-to-cover ratio is currently 2.3 days. Currently, 5.7% of the company’s shares are sold short.

X4 Pharmaceuticals Price Performance

Shares of XFOR stock opened at $0.30 on Friday. The firm has a fifty day simple moving average of $0.46 and a 200-day simple moving average of $0.54. The company has a market capitalization of $51.91 million, a PE ratio of -3.38 and a beta of 0.39. X4 Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $1.60. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Paula Ragan sold 76,473 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the sale, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at $489,323.70. The trade was a 6.57 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 202,663 shares of company stock valued at $91,198. 1.62% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC acquired a new position in shares of X4 Pharmaceuticals in the fourth quarter worth about $5,363,000. GSA Capital Partners LLP purchased a new stake in X4 Pharmaceuticals during the 3rd quarter worth approximately $340,000. JPMorgan Chase & Co. raised its position in shares of X4 Pharmaceuticals by 501.0% in the 4th quarter. JPMorgan Chase & Co. now owns 459,653 shares of the company’s stock valued at $337,000 after purchasing an additional 383,177 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of X4 Pharmaceuticals by 134.9% during the 4th quarter. Jane Street Group LLC now owns 583,483 shares of the company’s stock valued at $428,000 after buying an additional 335,036 shares during the last quarter. Finally, Deutsche Bank AG grew its position in shares of X4 Pharmaceuticals by 559.6% during the fourth quarter. Deutsche Bank AG now owns 267,628 shares of the company’s stock worth $195,000 after buying an additional 227,051 shares in the last quarter. 72.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $1.50 target price on shares of X4 Pharmaceuticals in a research note on Friday, February 7th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.